Dean W. Lim, M.D.

  • Clinical Professor, Department of Medical Oncology & Therapeutics Research
  • Medical Oncologist

Dean W. Lim, M.D.

Clinical Specialties
  • Medical Oncology
Areas of Expertise
  • Gastrointestinal Cancers
  • Head & neck oncology
Research Focus
  • GI & H&N Cancers
Other Languages Spoken
  • Mandarin
  • Tagalog
  • Fookien
Part of the City of Hope team since 1999, Dean W. Lim, M.D., says he still gets emotional when he's able to tell patients their cancer is in remission. “The patient will tear up... they're speechless.... they're just happy... I feel like crying with the patient too!”
 
Educated in the Philippines, Dr. Lim completed a fellowship in Hematology/Oncology at St. Luke's Roosevelt Hospital in New York City before arriving in California some 25 years ago. Well-versed in all aspects of oncology, he specializes in the treatment of head and neck cancer.
  • 1999 - present, Clinical Professor and Staff Physician, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
  • 2002 - 2003, Staff Physician, Riverside County Hospital, City of Hope Practice, Riverside, CA
  • 1999, Staff Physician, Huntington Memorial Hospital, Pasadena, CA
  • 1995 - 1999, Associate Oncologist/Hematologist, Private Practice, CareMore Medical Group, Brea, CA
  • 1990 - 1995, Staff Oncologist / Hematologist-Medical FHP Inc. HMO, Fountain Valley, CA
  • 1988 - 1995, Staff Internist Hospitalizing - FHP Primary Care M.D.-Locum Tenens on weekend FHP Clinics, Fountain Valley, CA
  • 1986 - 1987, Attending, St. Luke's Roosevelt Hospital Detox Unit, New York, NY
  • 1986 - 1987, E.R. Attending Cabrini Medical Center, New York, NY

Locations

Duarte

1500 East Duarte Road, Duarte, CA, 91010

Get Directions

Phone :  626-256-4673

Degrees

  • 1985 -1987, Fellowship, Hematology/Oncology, St. Luke's Roosevelt Hospital, New York, NY
  • 1980, University of the East, Ramon Magsaysay Memorial Medical Center, Manila, Philippines
  • 1976, University of the East, Manila, Philippines, B.S., Pre-Medicine

Fellowship

  • 1985 -1987, Fellowship, Hematology/Oncol

Residency

  • 1982 -1985, Residency, Internal Medicine
  • 1989, Board Certified, Medical Oncology
  • 1985, Board Certified, Internal Medicine

Lim D, Akman S, Margolin K, Carr BI, Leong L, Odujinrin O, Morgan RJ Jr, and Doroshow JH. Phase I trial of synkayvite (Vitamin K3, Menadiol Diphosphate) in advanced malignancy. Invest. New Drugs 23: 235-239, 2005.

Chow WA, Synold TW, Tetef ML, Longmate J, Frankel P, Lawrence J, Al-Kadhimi Z, Leong L, Lim D, Margolin K, Morgan RJ, Jr, Raschko J, Shibata S, Somlo G, Twardowski P, Yen Y, and Doroshow JH. Feasibility study of concurrent infusional dexrazoxane and dose-intensive doxorubicin administered over 96 hours for the treatment of advanced malignancies. Cancer Chemother. Pharmacol. 54: 241-248, 2004.

Somlo G, Frankel P, Chow W, Leong L, Margolin K, Morgan R Jr, Shibata S, Chu P, Forman S, Lim D, Twardowski P, Weitzel J, Alvarnas J, Kogut N, Schriber J, Fermin E, Damon L, and Doroshow JH. Prognostic indicators and survival in 120 patients with stage IIIB inflammatory breast carcinoma following dose-intense chemotherapy. J. Clin. Oncol. 22: 1839-1848, 2004.

Morgan RJ, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, Paz B, Chu D, Frankel P, and Stalter S. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies confined to the peritoneal cavity: Dose-limiting toxicity and pharmacokinetics. Clin. Cancer Res. 9: 461-467, 2004.

Shibata S, Frankel P, Leong L, Lim D, Margolin K, Morgan R, Somlo G, Synold T, Twardowski P, Doroshow JD. Phase I study of cisplatin (CDDP) in combination with ICRF-187 (ICRF) in the treatment of advanced malignancies. Proc. Amer. Soc. Clin. Oncol. 22: 164, 2003.

Morgan, R.J., Doroshow, J.H., Synold, T., Lim, D., Shibata, S., Margolin, K.A., Schwarz, R., Leong, L., Somlo, G., Twardowski, P., Yen, Y., Chow, W., Lin, P., Paz, B., Chu, D., Frankel, P. and Stalter S. Phase I trial of intraperitoneal (ip) docetaxel (D) in the treatment of advanced malignancies primarily confined to the peritoneal cavity: Dose-limiting toxicity (DLT) and pharmacokinetics (PK). Proc. Amer. Assoc. Cancer Res. 43: 551, #2741, 2002.

Doroshow JH, Margolin K, Chow W, Leong L, Lim D, McNamara M, Morgan R, Shibata S, Somlo G, Twardowski P, Weitzel J, Yen Y, Kogut N, Schriber J, Alvarnas J, Stalter S. High-dose chemotherapy with autologous stem cell rescue (PSCT) for relapsed nonseminomatous germ cell cancer (NSGCT): Effective salvage for poor-risk patients (pts) in first relapse. Proc. Amer. Soc. Clin. Oncol 21: 179a, # 714, 2002.

Newman EM, Longmate JA, Lenz H.-J, Carroll MI, Stalter SK, Lim D, Raschko JW, Shibata SI, Somlo G, Doroshow JH. Phase I and pharmacokinetic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine: a California Cancer Consortium study. Proc. Amer. Soc. Clin. Oncol. 21: 108a, #431, 2002.

Morgan R, Doroshow J, Synold T, Lim D, Shibata S, Margoln K, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, PazB, Chu D, Frankel P. Phase I trial of intraperitoneal Iip) doecetaxel (D) in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Proc. Amer. Soc. Clin. Oncol. 20: 93b, 2001.

Shibata S, Chow W, Frankel P, Leong L, Lim D, Longmate J, Margolin K, McNamara M, Morgan R, Raschko J, Somlo G, Synold T, Tetef M, Twardowski P, Yen Y, Doroshow J, Lenz H, Gandara D. A phase I trial of oxaliplatin (OX) in combination with gemcitabine (G): A California Consortium Trial. Proc. Amer. Soc. Clin. Oncol. 20: 96a, 2001

  • American Society of Clinical Oncology
  • Southern California Academy of Clinical Oncology
  • Southwest Oncology Group
  • National Comprehensive Cancer Network (NCCN) for Antiemesis and Eldely Task Force
Back To Top